Pfizer argues for regulatory coherence with orphans, like tafamidis
This article was originally published in Scrip
Executive Summary
In responding to the rejection on 25 January by English health ministers its one of its rare disease drugs, Vyndaqel, Pfizer took a side-swipe at the discrepancies between national and EU-level drug regulators, before insisting that it would continue to trying to get the drug to market in the UK.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.